@Epichemist Thx for that great post. Following your line of thought , Big Pharma should being adding weight to the next lot of preclinical animal trials that we are waiting to be announced.
Besides doing Ph3 trials , I would like to see FDA approvals for further Ph2 trials in those new indications.
So prospective buyers can see several more PH2 trials ready to go. Just like last time when they announced 4 ph2 trials .
If they have 2 successful ph3 trials it’s likely further expansion trials will be much shorter smaller and cheaper. The advocates for the next 100 indications will be banging on the FDA doors wanting access to 2591.
They definitely won’t want to be waiting 15 years.
Ann: Phase 2 trial shows significant improvements in Angelman, page-80
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |